MMP8
ENSG00000118113
Target class
Enzyme
Chromosome
11
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- MMP8
- Gene name
- Matrix metallopeptidase 8
- Gene symbol
- MMP8
- Previous gene symbols
- CLG1
- Protein name
- Neutrophil collagenase (EC 3.4.24.34) (Matrix metalloproteinase-8) (MMP-8) (PMNL collagenase) (PMNL-CL)
- Gene biotype
- Protein coding
- Gene family
- M10 matrix metallopeptidases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 3
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 49.68
- Tissue specificity (Gini)
- 0.943
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:4317
- Protein interaction confidence
- 0.819526
- Protein interaction partners
- 19
- R-HSA-1442490
- R-HSA-1474228
- R-HSA-1592389
- R-HSA-6798695
- End position
- 102727050
- Start position
- 102711796
- Chromosome
- 11
- Strand
- Reverse
- Cytoplasmic granule. Secreted, extracellular space, extracellular matrix . Note=Stored in intracellular granules.
- Vesicles
- Tissue specificity (tau)
- 0.994201
- Expression inequality (Gini)
- 0.943002
Expression in transcripts per million
- Whole Blood
- 49.68
- Spleen
- 9.43
- Lung
- 2.7
- Adipose - Visceral (Omentum)
- 0.31
- Adipose - Subcutaneous
- 0.3
Expression in transcripts per million
- Whole Blood49.68
- Spleen9.43
- Lung2.7
- Adipose - Visceral (Omentum)0.31
- Adipose - Subcutaneous0.3
- Cells - Cultured fibroblasts0.16
- Testis0.14
- Liver0.12
- Thyroid0.12
- Breast - Mammary Tissue0.12
- Artery - Coronary0.11
- Fallopian Tube0.1
- Pituitary0.1
- Artery - Aorta0.09
- Heart - Atrial Appendage0.09
- Brain - Spinal cord (cervical c-1)0.07
- Brain - Substantia nigra0.07
- Heart - Left Ventricle0.06
- Uterus0.06
- Kidney - Cortex0.06
- Minor Salivary Gland0.06
- Brain - Putamen (basal ganglia)0.06
- Brain - Amygdala0.05
- Brain - Hypothalamus0.05
- Brain - Frontal Cortex (BA9)0.05
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0022617
- GO:0030574
- GO:0032760
- GO:0035987
- GO:0005576
- GO:0031012
- GO:0035580
- GO:1904724
- GO:0004175
- GO:0004222
- GO:0004252
- GO:0008233
- GO:0008270
- GO:0043120
Related records
Trials (339)
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
- A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
- A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Novel Combination Oral Agent to Treat Acne Vulgaris
- A Phase II Study of Doxycycline in Relapsed NHL
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
- A Pilot Study of Inflammatory Markers in Alzheimer's Disease
- A Randomized Controlled Trial of Doxycycline Post Exposure Prophylaxis to Prevent Incident Bacterial STIs Among Women in the United States
- A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
- A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
Drugs (6)
- CTS-1027 Matrix metalloproteinase 8 inhibitor
- Doxycycline Matrix metalloproteinase 8 inhibitor
- Doxycycline anhydrous Matrix metalloproteinase 8 inhibitor
- Doxycycline calcium Matrix metalloproteinase 8 inhibitor
- Doxycycline hyclate Matrix metalloproteinase 8 inhibitor
- Rebimastat Matrix metalloproteinase 8 inhibitor